Financial reports
10-Q
2024 Q3
Quarterly report
12 Feb 24
10-Q
2024 Q2
Quarterly report
13 Nov 23
10-Q
2024 Q1
Quarterly report
14 Aug 23
10-K/A
2023 FY
Annual report (amended)
17 Jul 23
10-K
2023 FY
Annual report
13 Jul 23
NT 10-K
Notice of late annual filing
29 Jun 23
10-Q
2023 Q3
Quarterly report
24 Feb 23
NT 10-Q
Notice of late quarterly filing
14 Feb 23
Current reports
8-K
Amendments to Articles of Incorporation or Bylaws
19 Apr 24
8-K
Entry into a Material Definitive Agreement
10 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
26 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Jan 24
8-K
Important Update on Listing Status and Strategic Direction
3 Jan 24
8-K
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
13 Dec 23
8-K
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
21 Nov 23
8-K
Regulation FD Disclosure
14 Nov 23
8-K
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
14 Nov 23
8-K
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
13 Nov 23
Registration and prospectus
25-NSE
Exchange delisting
21 Mar 24
424B8
Prospectus unintentially filed late
11 Sep 23
POS AM
Prospectus update (post-effective amendment)
3 Aug 23
424B4
Prospectus supplement with pricing info
15 May 23
S-1/A
IPO registration (amended)
18 Apr 23
S-1
IPO registration
13 Mar 23
424B5
Prospectus supplement for primary offering
31 Jan 23
424B5
Prospectus supplement for primary offering
1 Apr 22
S-3
Shelf registration
16 Mar 22
424B5
Prospectus supplement for primary offering
23 Jul 21
Proxies
PRE 14C
Preliminary information
19 Apr 24
DEFA14A
Additional proxy soliciting materials
17 Jan 24
DEF 14A
Definitive proxy
17 Jan 24
PRE 14A
Preliminary proxy
7 Dec 23
DEFA14A
Additional proxy soliciting materials
8 Sep 23
DEF 14A
Definitive proxy
8 Sep 23
PRE 14A
Preliminary proxy
10 Aug 23
DEF 14C
Information statement
18 Apr 23
PRE 14C
Preliminary information
7 Apr 23
DEF 14A
Definitive proxy
20 Jul 22
Other
EFFECT
Notice of effectiveness
8 Aug 23
EFFECT
Notice of effectiveness
15 May 23
CORRESP
Correspondence with SEC
11 May 23
CORRESP
Correspondence with SEC
10 May 23
UPLOAD
Letter from SEC
4 May 23
CORRESP
Correspondence with SEC
18 Apr 23
UPLOAD
Letter from SEC
29 Mar 23
EFFECT
Notice of effectiveness
29 Mar 22
CORRESP
Correspondence with SEC
24 Mar 22
UPLOAD
Letter from SEC
23 Mar 22
Ownership
SC 13G
Alyeska Investment Group, L.P.
14 Feb 24
4
Arash Ghadar-Ghadr
9 Jan 24
3
Arash Ghadar-Ghadr
9 Jan 24
4
Salim Natha
1 Feb 22
4
Thomas Peter Moore
1 Feb 22
4
Justin James Mclarney
1 Feb 22
4
Timothy Christopher Johnson
1 Feb 22
4
Dewan Fazlul Hoque Chowdhury
1 Feb 22
4
Bashir Timol
1 Feb 22
3
Thomas Peter Moore
10 Nov 21